JP2012505837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505837A5 JP2012505837A5 JP2011531312A JP2011531312A JP2012505837A5 JP 2012505837 A5 JP2012505837 A5 JP 2012505837A5 JP 2011531312 A JP2011531312 A JP 2011531312A JP 2011531312 A JP2011531312 A JP 2011531312A JP 2012505837 A5 JP2012505837 A5 JP 2012505837A5
- Authority
- JP
- Japan
- Prior art keywords
- annexin
- composition
- effective
- amount
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000672 Annexin A5 Proteins 0.000 claims description 68
- 102000004121 Annexin A5 Human genes 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 230000000770 proinflammatory effect Effects 0.000 claims description 16
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 230000004768 organ dysfunction Effects 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10639008P | 2008-10-17 | 2008-10-17 | |
| US61/106,390 | 2008-10-17 | ||
| PCT/CA2009/001469 WO2010043045A1 (en) | 2008-10-17 | 2009-10-16 | Annexin and its use to treat inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505837A JP2012505837A (ja) | 2012-03-08 |
| JP2012505837A5 true JP2012505837A5 (enExample) | 2012-12-06 |
| JP5590621B2 JP5590621B2 (ja) | 2014-09-17 |
Family
ID=42106169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531312A Active JP5590621B2 (ja) | 2008-10-17 | 2009-10-16 | 炎症性障害の処置を処置するためのアネキシンおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9192649B2 (enExample) |
| EP (1) | EP2349321B1 (enExample) |
| JP (1) | JP5590621B2 (enExample) |
| CN (1) | CN102256617B (enExample) |
| CA (1) | CA2740557C (enExample) |
| WO (1) | WO2010043045A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010043045A1 (en) | 2008-10-17 | 2010-04-22 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
| AU2009328507A1 (en) | 2008-12-19 | 2011-07-14 | Medirista Biotechnologies Ab | Oxidized cardiolipin as a novel pro-inflammatory factor |
| WO2011160845A2 (en) | 2010-06-24 | 2011-12-29 | Medirista Biotechnologies Ab | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| CN102690345B (zh) * | 2011-03-24 | 2014-03-19 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
| BR112013032088B1 (pt) * | 2011-06-15 | 2020-11-24 | Resother Pharma Aps | produtos farmacêuticos anti-inflamatórios |
| EP2817327A1 (en) | 2012-02-21 | 2014-12-31 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Tim receptors as virus entry cofactors |
| BR112014021065A8 (pt) | 2012-02-21 | 2018-04-24 | Centre Nat Rech Scient | receptores tam como cofatores de entrada do vírus |
| WO2014077575A1 (ko) * | 2012-11-13 | 2014-05-22 | 다인바이오 주식회사 | 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 |
| GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| GB201702144D0 (en) * | 2017-02-09 | 2017-03-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
| JP2021527094A (ja) * | 2018-06-12 | 2021-10-11 | ユニフェルシテイト マーストリヒトＵｎｉｖｅｒｓｉｔｅｉｔ Ｍａａｓｔｒｉｃｈｔ | 早産新生児の低酸素性虚血性脳症の治療方法 |
| CN109529017B (zh) * | 2018-12-25 | 2022-06-14 | 江苏靶标生物医药研究所有限公司 | 一种膜联蛋白v的应用 |
| US20220193192A1 (en) * | 2019-08-30 | 2022-06-23 | Suzhou Yabao Pharmaceutical R&D Co Ltd | Methods of treating a traumatic brain injury |
| US11357823B2 (en) * | 2019-08-30 | 2022-06-14 | Suzhou Yabao Pharmaceutical R&D Co., Ltd | Method for treating cerebral stroke |
| CN112057623A (zh) * | 2020-06-03 | 2020-12-11 | 江苏靶标生物医药研究所有限公司 | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 |
| US20230374091A1 (en) * | 2020-10-09 | 2023-11-23 | London Health Sciences Centre Research Inc. | Annexin a5 compositions and methods |
| CN112618696B (zh) * | 2020-12-14 | 2023-05-05 | 南京大学 | Annexin A5在制备治疗胆汁淤积药物中的应用 |
| CN115245559B (zh) * | 2021-04-25 | 2026-05-01 | 上海萨美细胞技术有限公司 | 一种用于治疗肺损伤的药物 |
| WO2023143463A1 (en) * | 2022-01-30 | 2023-08-03 | Nanjing Reju Therapeutics , Inc. | Fusion protein and application thereof |
| CN118001375A (zh) * | 2023-04-12 | 2024-05-10 | 上海萨美细胞技术有限公司 | 一种用于难愈性创面修复的药物 |
| CN119097689A (zh) * | 2023-06-08 | 2024-12-10 | 上海萨美细胞技术有限公司 | 一种用于治疗卵巢功能不全的药物 |
| CN118001372A (zh) * | 2023-07-04 | 2024-05-10 | 上海萨美细胞技术有限公司 | 膜联蛋白在抗衰老中的用途 |
| CN119158000B (zh) * | 2023-10-25 | 2025-07-18 | 上海萨美细胞技术有限公司 | 一种用于治疗肺纤维化的药物 |
| WO2025129329A1 (en) * | 2023-12-23 | 2025-06-26 | London Health Sciences Centre Research Inc. | Methods for treatment of sepsis |
| CN118203650B (zh) * | 2024-01-26 | 2025-04-29 | 上海萨丽斐生物科技有限公司 | 一种用于治疗色素沉着的药物 |
| CN118846001B (zh) * | 2024-07-09 | 2025-09-02 | 上海萨丽斐生物科技有限公司 | 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339285A3 (en) * | 1988-03-31 | 1989-11-29 | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) | Recombinant endonexin ii |
| US5229367A (en) * | 1991-01-21 | 1993-07-20 | Sclavo S.P.A. | Antiinflammatory peptide derived from human lipocortin V |
| CA2185535C (en) | 1994-04-11 | 2000-10-24 | Christiaan Peter Maria Reutelingsperger | A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample |
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US20030152513A1 (en) | 2001-09-06 | 2003-08-14 | Imetrix, Inc. | Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector |
| CN1659180B (zh) | 2002-06-06 | 2010-06-02 | 温子坚 | 新型的重组抗凝血蛋白 |
| ES2356364T3 (es) | 2004-04-15 | 2011-04-07 | Athera Biotechnologies Ab | Anexina v para prevenir la ruptura de la placa. |
| WO2009001224A2 (en) | 2007-06-22 | 2008-12-31 | Eth Zurich | Antivirals |
| EP2178896A1 (en) * | 2007-07-31 | 2010-04-28 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| HRP20120797T1 (hr) | 2007-12-18 | 2012-12-31 | Athera Biotechnologies Ab | Spojevi i postupci za lijeäśenje vaskularne bolesti |
| JP2011512393A (ja) | 2008-02-22 | 2011-04-21 | アセラ・バイオテクノロジーズ・アーベー | 再狭窄の予防または治療のための化合物および方法 |
| WO2010043045A1 (en) | 2008-10-17 | 2010-04-22 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
-
2009
- 2009-10-16 WO PCT/CA2009/001469 patent/WO2010043045A1/en not_active Ceased
- 2009-10-16 CN CN200980150927.0A patent/CN102256617B/zh active Active
- 2009-10-16 CA CA2740557A patent/CA2740557C/en active Active
- 2009-10-16 JP JP2011531312A patent/JP5590621B2/ja active Active
- 2009-10-16 EP EP09820159.3A patent/EP2349321B1/en not_active Revoked
- 2009-10-16 US US13/124,330 patent/US9192649B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Torres-Espín et al. | Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury | |
| Kim et al. | Mechanisms of radiation-induced skin injury and implications for future clinical trials | |
| JP2007530543A5 (enExample) | ||
| Tetè et al. | IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation | |
| Corrigan et al. | The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains | |
| JP2006516116A5 (enExample) | ||
| CN111542335A (zh) | 炎症性肠病的治疗药 | |
| Yang et al. | Effects of metformin on lipopolysaccharide-induced depressive-like behavior in mice and its mechanisms | |
| SG188144A1 (en) | Alpha 7 nicotinic agonists and antipsychotics | |
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| CA2387486A1 (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
| JP2017536380A5 (enExample) | ||
| JP2008534503A5 (enExample) | ||
| Lan | Macrophage-myofibroblast transition in kidney disease | |
| Cheng et al. | Anti-inflammatory effect of stem cells against spinal cord injury via regulating macrophage polarization | |
| JP2018530577A (ja) | 神経変性疾患の治療のための方法および組成物 | |
| RU2009136424A (ru) | Композиция и способ лечения папилломавируса и саркоидов лошадей | |
| US10639296B2 (en) | Methods to mitigate injury from radiation exposure | |
| JP2009538935A5 (enExample) | ||
| CN102552280A (zh) | 甘草酸或盐及其衍生物的制药用途 | |
| JP2014512369A5 (enExample) | ||
| CN110225922B (zh) | 用于促进血管生成的剂及其方法和用途 | |
| CN105854018A (zh) | Wnt抑制剂在制备治疗造血再生障碍性疾病药物中的应用 | |
| CN117883459A (zh) | 氨基葡萄糖的应用 | |
| CN105030822B (zh) | 有机无机杂化多阴金属氧酸盐化合物的用途 |